Division of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Keunchil Park , Jong-Seok Lee , Ki Hyeong Lee , Joo-Hang Kim , Young Joo Min , Jae Yong Cho , Ji-Youn Han , Bong-Seog Kim , Jin-Soo Kim , Dae Ho Lee , Jin Hyoung Kang , Eun Kyung Cho , In-Jin Jang , Jina Jung , Hyo-Yeon Kim , Hui Jung Sin , Jeewoong Son , Jong Soo Woo , Dong-Wan Kim
Background: HM61713 is an orally available EGFR mutation-specific inhibitor with sparing EGFR WT tumors that previously showed promising efficacy in T790M positive tumors at the dose of 300 mg (overall response rate; 29.2%). We report here on updated data from the ongoing phase I/II study of HM61713 in pts with advanced NSCLC who had failed previous EGFR-TKIs (NCT01588145). Methods: Advanced NSCLC pts with EGFR mutation positive tumor were enrolled in dose escalation cohort and received doses ranging from 75-1200 mg/day. After safety evaluation, separate expansion cohorts opened for pts who failed prior EGFR TKI pts at 800 mg QD dose, respectively to investigate efficacy and tolerability of HM61713 in pts with centrally confirmed T790M positive NSCLC. Results: As of 15 Dec 2014, 173 patients were enrolled, 55 and 118 in dose escalation and expansion parts, respectively. Maximum tolerated dose (MTD) was established as 800 mg once daily (QD). Dose limiting toxicities (DLTs) included abdominal pain, diarrhoea, idiosyncratic drug reaction, and elevation of aspartate aminotransferase, alanine aminotransferase, amylase and lipase. Treatment-related adverse events occurred in 87.3% of 165 pts; mainly diarrhea, rash, skin exfoliation, nausea, pruritus, decreased appetite and dry skin. In the 34 pts with centrally confirmed T790M who received HM61713 with a dose more than 650 mg, the overall response rate was 58.8%, (10 confirmed/10 unconfirmed partial responses) and 13 pts achieved disease stabilization (disease control rate; 97.1%). Updated data will be presented at the meeting. Conclusions: HM61713 showed an encouraging clinical anti-tumor activity with good tolerability in pts with T790M positive NSCLC. Clinical trial information: NCT01588145
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Jianchun Duan
2024 ASCO Annual Meeting
First Author: Mariana da Rocha Almeida Brandao
2021 ASCO Annual Meeting
First Author: Pasi A. Janne
2022 ASCO Annual Meeting
First Author: Elaine Shum